Veelken H - Search Results

1

10-year stability of clinical-grade serum-free γ-retroviral vector-containing medium.

Herbst F, Ball CR, Zavidij O, Fessler S, Schmidt M, Veelken H, von Kalle C, Glimm H. Herbst F, et al. Among authors: veelken h. Gene Ther. 2011 Feb;18(2):210-2. doi: 10.1038/gt.2010.126. Epub 2010 Nov 11. Gene Ther. 2011. PMID: 21068779

2

Systemic hematological effects of granulocyte colony-stimulating factor produced by irradiated gene-transfected fibroblasts.

Rosenthal FM, Kulmburg P, Früh R, Pfeifer C, Veelken H, Mackensen A, Köhler G, Lindemann A, Mertelsmann R. Rosenthal FM, et al. Among authors: veelken h. Hum Gene Ther. 1996 Nov 10;7(17):2147-56. doi: 10.1089/hum.1996.7.17-2147. Hum Gene Ther. 1996. PMID: 8934228

3

Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy.

Veelken H, Jesuiter H, Mackensen A, Kulmburg P, Schultze J, Rosenthal F, Mertelsmann R, Lindemann A. Veelken H, et al. Hum Gene Ther. 1994 Oct;5(10):1203-10. doi: 10.1089/hum.1994.5.10-1203. Hum Gene Ther. 1994. PMID: 7849093

4

Systematic evaluation of chimeric marker genes on dicistronic transcription units for regulated expression of transgenes in vitro and in vivo.

Veelken H, Re D, Kulmburg P, Rosenthal FM, Mackensen A, Mertelsmann R, Lindemann A. Veelken H, et al. Hum Gene Ther. 1996 Oct 1;7(15):1827-36. doi: 10.1089/hum.1996.7.15-1827. Hum Gene Ther. 1996. PMID: 8894674

5

Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses.

Warncke M, Dodero A, Dierbach H, Follo M, Veelken H. Warncke M, et al. Among authors: veelken h. J Immunol Methods. 2006 Mar 20;310(1-2):1-11. doi: 10.1016/j.jim.2005.09.012. Epub 2005 Oct 25. J Immunol Methods. 2006. PMID: 16337648

6

Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.

Kiesel H, Müller AM, Schmitt-Graeff A, Veelken H. Kiesel H, et al. Among authors: veelken h. Cancer Biol Ther. 2009 Feb;8(4):319-21. doi: 10.4161/cbt.8.4.7547. Epub 2009 Feb 2. Cancer Biol Ther. 2009. PMID: 19182535 Free article.

7

Expansion and fibronectin-enhanced retroviral transduction of primary human T lymphocytes for adoptive immunotherapy.

Stockschläder M, Haiss M, Exner S, Schmah O, Veelken H, Follo M, Rüger R, Finke J. Stockschläder M, et al. Among authors: veelken h. J Hematother Stem Cell Res. 1999 Aug;8(4):401-10. doi: 10.1089/152581699320162. J Hematother Stem Cell Res. 1999. PMID: 10634178

8

Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial.

Veelken H, Rosenthal FM, Schneller F, von Schilling C, Guettler IC, Herrmann F, Mertelsmann R, Lindemann A. Veelken H, et al. Biotechnol Ther. 1992;3(1-2):1-14. Biotechnol Ther. 1992. PMID: 1305889 Clinical Trial.

9

Cytokine gene transfer in cancer therapy.

Cao L, Kulmburg P, Veelken H, Mackensen A, Mézes B, Lindemann A, Mertelsmann R, Rosenthal FM. Cao L, et al. Among authors: veelken h. Stem Cells. 1998;16 Suppl 1:251-60. doi: 10.1002/stem.5530160831. Stem Cells. 1998. PMID: 11012169 Review.

10

Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma.

Lahn M, Fisch P, Köhler G, Kunzmann R, Hentrich I, Jesuiter H, Behringer D, Muschal B, Veelken H, Kulmburg P, Iklé DN, Lindemann A. Lahn M, et al. Among authors: veelken h. Eur Urol. 1999 Jan;35(1):70-80. doi: 10.1159/000019821. Eur Urol. 1999. PMID: 9933797 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters